Inclusion Criteria:

- Histologically or cytologically confirmed solid malignancy

- Metastatic or unresectable disease

- Standard curative or palliative measures do not exist or are no longer effective

- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques
or as ≥ 10 mm with spiral CT scan

- No known brain metastases

- ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)

- Life expectancy > 12 weeks

- Leukocytes ≥ 3,000/mm^3

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9 g/dL

- Total bilirubin normal

- AST/ALT ≤ 2.5 times upper limit of normal

- Serum creatinine normal OR creatinine clearance ≥ 60 mL/min

- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or
hypokalemia, defined as < lower limit of normal despite adequate electrolyte
supplementation

- QTc ≤ 450 msec in males and a QTc ≤ 470 in females, as measured by ECG using Bazett's
formula

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use 2 forms of contraception (i.e., barrier contraception and 1
other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months
after completion of study treatment

- Willing to undergo 2 tumor biopsies (unless medically contraindicated)

- Able to swallow medication

- No malabsorption syndrome or other condition that would interfere with intestinal
absorption

- No diarrhea ≥ grade 2 not under control with standard antidiarrhea medications

- No uncontrolled concurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia other than chronic, stable atrial fibrillation

- Psychiatric illness or social situations that would limit compliance with study
requirements

- No history of risk factors for QT interval prolongation including, but not limited
to, a family or personal history of any of the following:

- Long QT syndrome

- A history of torsades de pointes

- Recurrent syncope without known etiology

- Sudden unexpected death

- Female patients may not donate ova during or after study treatment

- No blood donation during and for ≥ 12 months after completion of study treatment

- No serologic positivity for hepatitis A, B, or C; history of liver disease; or other
forms of hepatitis or cirrhosis

- No HIV-positive patients on combination antiretroviral therapy

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in
this study

- No other concurrent agents or therapies administered with the intent to treat the
patient's malignancy

- No prior gamma-secretase inhibitors

- Any number of prior treatment regimens allowed

- At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for prior
carmustine or mitomycin C)

- Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy for
symptomatic palliation

- Recovered from the adverse events due to prior therapy to < CTCAE grade 2 (except
alopecia)

- No other concurrent investigational agents

- No concurrent medications with narrow therapeutic indices that are metabolized by
cytochrome P450, including warfarin sodium (Coumadin®)

- No concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4

- No concurrent medications or food that may interfere with the metabolism of
gamma-secretase inhibitor RO4929097 including ketoconazole, grapefruit, or grapefruit
juice

- No antiarrhythmics or other concurrent medications with known potential to prolong QT
interval